今天分享的是：2025年全球零售力量报告-德勤 报告共计：87页 德勤《2025年全球零售力量报告》聚焦全球零售行业发展态势，揭示行业在挑战中通过技术创新、效率优化与模式变革寻求突 破的核心逻辑。 2023财年，全球零售250强企业零售收入达6.03万亿美元，同比增长3.6%，净利润率3.7%。其中，多元化产品领域以6.3%的五年 复合增长率居首，服装与配饰行业净利润率达9.8%。沃尔玛、亚马逊等头部企业通过AI技术提升运营效率，如沃尔玛利用生成 式AI优化超8.5亿条产品数据，亚马逊推出Sequoia机器人系统提升库存效率75%。 报告指出四大趋势重塑行业格局。一是战略性运营效率成为核心，企业借助自动化与供应链优化降本增效，如家得宝引入谷歌 云AI技术改善库存管理，Kroger与Ocado合作升级自动化履约中心。二是AI驱动技术转型加速，生成式AI被广泛应用于个性化推 荐与内容创作，Shein、Coupang等企业依托算法实现年均超40%的收入增长。三是可持续发展从理念转为实践，沃尔玛提前六年 完成"兆吨计划"，Aldi取消塑料购物袋并推动包装100%可回收。四是替代收入来源拓展，零售媒体网络规模2025年 ...

Core Viewpoint - The collective performance briefing held by Shenzhen Stock Exchange highlighted the overseas expansion strategies of four listed companies, showcasing their global market ambitions and operational achievements [1][2]. Group 1: Company Overview - The four companies participating in the briefing are typical representatives of overseas expansion, with significant global operations [1]. - XW Communication has a global presence with 26 subsidiaries, 11 R&D centers, and 5 main production bases across 8 countries and 18 regions [3]. - Hanshu Technology has achieved international strategic layout early on, with overseas revenue reaching 4.222 billion yuan in 2024 [3]. Group 2: Overseas Expansion Strategies - Meihai Medical is advancing its overseas operations with nearly ten years of experience and is currently developing its third phase of the Malaysia industrial base [2]. - Saiwei Times has expanded its overseas supply chain since 2024, establishing a factory in Vietnam and achieving significant growth in the European market [2]. - XW Communication is focusing on providing terminal equipment connectors and antennas to overseas clients, planning to onboard more domestic and international customers [3]. Group 3: R&D Investments - Hanshu Technology is investing in AI technology for retail applications, utilizing Microsoft Azure Open AI to develop innovative AI solutions [4]. - XW Communication is increasing R&D in core materials, with an investment of approximately 708 million yuan in 2024, accounting for 8.10% of its revenue [5]. - Meihai Medical's R&D investment for 2024 is 141 million yuan, a year-on-year increase of 16.75%, focusing on various strategic growth areas [5].